Diabetic peripheral neuropathy (DPN) is among the most common and consequential complications of diabetes, yet it frequently develops silently for years before a patient notices anything is wrong. Because intact protective sensation is the body’s primary defense against foot injury, the loss of that sensation is the single most important step on the path toward foot ulceration, infection, and lower-limb amputation. Understanding how DPN is detected—and why detecting it early changes outcomes—is fundamental to diabetic foot health.
How Common Is Diabetic Peripheral Neuropathy?
Diabetic neuropathy affects roughly half of all people living with diabetes over the course of their disease, most often presenting as a distal symmetric polyneuropathy that begins in the toes and feet and progresses proximally in a “stocking” distribution. Its development is driven by a combination of chronic hyperglycemia, abnormal lipid metabolism, oxidative stress, mitochondrial dysfunction, and inflammation, which together damage peripheral nerve fibers. The clinical picture ranges from painful, burning, or tingling sensations to the more dangerous progressive numbness, because the loss of pain perception removes the warning system that normally prompts a person to notice a blister, a pressure point, or a foreign object in a shoe.
Neuropathy in diabetes is not limited to the sensory nerves of the feet. Cardiovascular autonomic neuropathy—damage to the nerves that regulate heart rate and blood pressure—affects approximately one in five people with diabetes and can begin even at the prediabetes stage, underscoring that nerve injury often starts earlier than many patients and clinicians assume.
Why Early Detection Matters
The clinical rationale for screening is straightforward: a patient who has lost protective sensation can sustain a significant wound without feeling it. Once neuropathy is identified, the level of risk can be graded and care intensified accordingly—more frequent foot examinations, structured education, appropriate footwear, and earlier intervention when problems arise. Risk stratification frameworks such as the International Working Group on the Diabetic Foot (IWGDF) system are widely used to match the intensity of preventive care to a person’s individual risk of ulceration.
Education is a crucial part of this process. Research using validated patient questionnaires has shown that understanding of foot complications is often weakest among lower-risk patients, who may not yet appreciate that a diabetic foot ulcer can be entirely painless. This gap highlights why detection should always be paired with clear, accessible explanation of what neuropathy means and how daily foot care can prevent serious complications.
How Neuropathy Is Detected
Screening for DPN does not require sophisticated equipment, which is part of why it is so valuable in everyday practice. The cornerstone bedside tests assess whether protective sensation remains intact: the 10-gram Semmes-Weinstein monofilament, which is pressed against specific points on the sole, and a 128-Hz tuning fork for vibration perception. These are commonly combined with assessment of pinprick sensation and ankle reflexes.
Simplified Screening Tools
One practical advance has been the validation of simplified tests that require no equipment at all. The Ipswich Touch Test, in which an examiner lightly touches the tips of specific toes, was evaluated in a systematic review and meta-analysis that pooled multiple studies. Compared with the 10-gram monofilament as the reference standard, the test demonstrated a pooled sensitivity of about 0.77 and a specificity of about 0.96, with an area under the curve of roughly 0.90. Its strong agreement with established methods makes it well suited to primary care settings, remote regions, and even self-monitoring by patients and caregivers.
Emerging Diagnostic Methods
Newer technologies aim to detect nerve injury earlier than traditional bedside tests can. Corneal confocal microscopy, a rapid and non-invasive imaging method that visualizes the small nerve fibers of the cornea, has emerged as a promising marker of small-fiber damage, alongside developing biomarker-based tests. For autonomic neuropathy, wearable devices that monitor heart rate variability offer a simplified and cost-effective route to earlier detection. These tools are expanding the window in which nerve damage can be identified—ideally before protective sensation is lost.
Management Foundations
Disease-modifying treatments that reverse established nerve damage remain elusive, so current management centers on slowing progression and controlling symptoms. Optimizing blood glucose, addressing lipids and other cardiovascular risk factors, and adopting lifestyle modifications form the foundation, supported by multidisciplinary care. For people who have already lost sensation, the emphasis shifts firmly to prevention of injury through regular foot inspection, suitable footwear, and prompt attention to any skin breakdown. Research into neuroprotective agents and regenerative approaches continues, but for now early identification followed by consistent preventive care offers the clearest path to protecting the diabetic foot.
Key Takeaways
Diabetic peripheral neuropathy is common, often silent, and the leading antecedent of diabetic foot complications. It can be detected reliably with simple, inexpensive bedside tests—and increasingly with equipment-free tools and advanced imaging that catch nerve injury earlier. Because the loss of protective sensation removes the body’s natural warning system, early detection paired with patient education and structured preventive care remains the most effective strategy for reducing ulceration and amputation risk.
References
Yang Y, Zhao B, Wang Y, et al. Diabetic neuropathy: cutting-edge research and future directions. Signal Transduction and Targeted Therapy. 2025;10(1):132. doi:10.1038/s41392-025-02175-1.
Zhao N, Xu J, Zhou Q, et al. Application of the Ipswich Touch Test for diabetic peripheral neuropathy screening: a systematic review and meta-analysis. BMJ Open. 2021;11(10):e046966. doi:10.1136/bmjopen-2020-046966.
Eleftheriadou A, Spallone V, Tahrani AA, Alam U. Cardiovascular autonomic neuropathy in diabetes: an update with a focus on management. Diabetologia. 2024;67(12):2611-2625. doi:10.1007/s00125-024-06242-0.
García-Madrid M, López-Moral M, Tardáguila-García A, et al. Disease knowledge and behavior regarding the diabetic foot in persons at different risks for foot ulceration according to the International Working Group on the Diabetic Foot guidelines. Journal of the American Podiatric Medical Association. 2024;114(5). doi:10.7547/22-087.
Comments
